David – Interview 34
David volunteered for a placebo-controlled trial of a new treatment derived from mouse DNA to improve asthma symptoms. He later discovered he was in the group taking a lower dose of the treatment, but he would not have minded being in the placebo group.
David has had asthma all his life. He was invited through his GP to take part in a hospital trial of a new treatment for asthma, derived from mouse DNA, which aims to reduce the immune system’s reaction to things which trigger asthmatic attacks. There were three groups in the trial, one taking a placebo, one taking a lower dose of the new treatment and one taking a higher dose. At the end of the trial David found out he had been in the low dose group, but neither he nor the doctor knew this during the trial (a double-blind; trial).
The intervention lasted several months and involved several visit to hospital for an injection in the buttock (which was quite painful) as well as blood tests and peak flow tests of his lung function. In between visits David had to take his own peak flow readings three times every day and fill in a chart, which he occasionally forgot to do. There was a generous expenses allowance for taking part in the trial, which at the time was appealing as David was out of work, but in fact given the amount of effort and travelling involved in taking part David felt this was reasonable.
His main reason for taking part was because he was interested in the condition and thought he would find out more about it and also help other people. He was not particularly worried which group he was in, in fact he would have found it quite interesting to be in the placebo group and see if he personally experienced any placebo effect. Not long after he had his first injection, there was a lot of coverage in the press about this type of DNA-based treatment, suggesting it was potentially dangerous, and he did have some second thoughts. But he stayed in because he;d already had one injection and took the view that it was too late and any damage would have already been done.
His symptoms did improve to some extent during the trial, and at the end the doctor showed him that his peak flow readings had also improved. David felt he got excellent care from the doctor running the trial and enjoyed being able to talk to him. He would if anything have liked more scientific information, even if it was hard to understand, to help him look into the press stories in more detail and understand how accurate they were. He was given a website address where he would later be able to find results from the trial but he hasn’t looked yet. He would like to see more research into long-term treatments for asthma which might reduce people’s dependence on inhaled medication to control attacks.